Novartis Pharmaceuticals Canada Inc. 385 Bouchard Blvd. Dorval, Quebec Canada H9S 1A9

First Page		Document Content
Date: 2014-11-17 07:51:16 Anatomy Combination drugs Enantiopure drugs Prodrugs Antihypertensive agents Heart failure Enalapril Novartis LCZ696 Pharmacology Medicine ACE inhibitors		Novartis Pharmaceuticals Canada Inc. 385 Bouchard Blvd. Dorval, Quebec Canada H9S 1A9 Add to Reading List Source URL: www.novartis.ca Download Document from Source Website File Size: 519,27 KB Share Document on Facebook

	平野医薬ニュース第 266 号 12/12 ２０１２．１２Ｎ o.２６６ ◆左室駆出率の保持された心不全におけるアンジオテンシン受容体･ネプリライシン阻害薬 LCZ696◆ DocID: 1k1CN - View Document
	Novartis Pharmaceuticals Canada Inc. 385 Bouchard Blvd. Dorval, Quebec Canada H9S 1A9 www.novartis.ca DocID: 19imV - View Document
	MEDIA STATEMENT • MEDIA STATEMENT • MEDIA STATEMENT Investigational heart failure medicine LCZ696 (sacubitril/valsartan) receives Promising Innovative Medicine designation in the UK PIM designation is the first s DocID: 15VUR - View Document
	Novartis Pharmaceuticals Canada Inc. 385 Bouchard Blvd. Dorval, Quebec Canada H9S 1A9 DocID: FyHg - View Document
$Long term efficacy and safety comparison of the angiotensin receptor neprilysin inhibitor (ARNi), LCZ696, and valsartan, in patients with heart failure and preserved ejection fraction: A randomized, double blind, morbidi$	Long term efficacy and safety comparison of the angiotensin receptor neprilysin inhibitor (ARNi), LCZ696, and valsartan, in patients with heart failure and preserved ejection fraction: A randomized, double blind, morbidi DocID: tk0Q - View Document